Table 1.

Participant characteristics at entry and tumor characteristics for women included in the analyses by BMI

STAR postmenopausal (N = 19,488)P-1 postmenopausal (N = 6,379)P-1 premenopausal (N = 5,864)
BMIBMIBMI
<25.025.0–29.9≥30.0<25.025.0–29.9≥30.0<25.025.0–29.9≥30.0
Participant characteristic (%)
Total number of participants5,8706,7036,9152,2042,1881,9872,5961,7851,483
Age, y
 ≤499.47.710.07.67.29.481.777.878.9
 50–5951.048.949.831.129.531.117.621.620.6
 ≥6039.643.440.261.363.359.60.70.70.5
Treatment
 Placebon/an/an/a49.251.750.050.250.150.4
 Tamoxifen50.549.849.750.848.350.049.849.949.6
 Raloxifene49.550.250.3n/an/an/an/an/an/a
5-year predicted breast cancer riska
 ≤2.0011.310.811.120.923.022.527.330.333.6
 2.01–3.0028.729.732.027.726.829.032.532.732.8
 3.01–5.0032.631.530.430.229.528.726.023.122.3
 ≥5.0127.428.126.421.220.719.814.113.911.3
History of diabetes
 No98.295.789.298.095.589.998.697.794.1
 Yes1.84.310.82.04.510.11.42.35.9
History of estrogen use
 No25.626.530.645.645.751.089.686.988.4
 Yes74.473.569.454.454.349.010.413.111.6
History of oral contraceptive use
 No31.831.933.856.259.556.818.520.623.3
 Yes68.268.166.243.840.543.281.579.476.7
History of smoking, y
 None55.555.255.753.856.857.053.951.656.3
 <1514.112.511.910.08.98.617.715.414.8
 15–3419.421.521.821.121.221.427.431.327.4
 ≥3510.310.19.914.712.912.60.81.51.3
 Unknown0.70.70.70.50.30.50.20.30.2
Tumor characteristic (%)
Total number of cases159191207424837434538
Tumor size
 ≤1.035.839.331.935.747.951.439.522.223.7
 1.1–3.056.049.754.647.647.945.941.962.260.5
 ≥3.15.09.48.714.34.22.718.615.615.8
 Unknown3.11.64.82.400000
Nodal status
 Negative74.273.371.569.070.881.165.157.860.5
 Positive21.421.524.623.822.913.532.637.831.6
 Unknown4.45.23.97.16.35.42.34.47.9
ER status
 Negative25.825.123.221.416.721.625.640.026.3
 Positive68.673.374.471.472.973.062.855.665.8
 Unknown5.71.62.47.110.45.411.64.47.9

Abbreviation: n/a, not applicable.

  • aDetermined by the Gail model.